Burns Market by DelveInsight

Burns Market by DelveInsight

DelveInsight's Burns Market Insights report proffers a detailed comprehension of Burns market size by treatment, epidemiology, emerging therapies, Burns market drivers, market barriers, and ongoing clinical trials. The report also provides an understanding of Burns market share of the individual therapies, current and forecasted Burns market size from 2018 to 2030 segmented into 7MM (the US, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the major takeaways from the Burns Market Report: 

• The Burns market size was USD 830 million in 2020 in the United States. DelveInsight estimates suggest that the United States had the highest incident population of burn injuries that required medical treatment. The market size of Burns is expected to grow at a CAGR of 1.96% in the 7MM for the study period 2018-2030.
• The Burns pipeline therapies include DenovoSkin, CellMist System, MW-III, and others, which may improve the treatment dynamics in the upcoming future.
• Major pharma giants working proactively in the Burns therapeutic market include CUTISS AG, Skingenix, Polynovo, Mallinckrodt Pharmaceuticals, Kerecis, MediWound Germany GmbH, Kaken Pharmaceutical Co., Avita Medical, Vericel Corporation, KeraNetics, Integra Life Sciences Corporation, Medline Industries, Anika Therapeutics, ACell, Amryt Pharma, Skingenix, RenovaCare, and many more.
• The Burns market is expected to be driven by factors such as the increasing incidence, availability of a wide range of treatment options, and advancements in burn care treatments and products.
• The Burns market may be hampered by several factors including stringent regulatory guidelines for the approval of new treatment or medicine and high cost for the treatment.
• A major breakthrough in Burns treatment is a bio-engineered DenovoSkin which is being developed by  CUTISS AG.

Download Burns Market sample to understand the comprehensive treatment scenario @ https://www.delveinsight.com/report-store/burns-market

Burns: Overview 

A Burn takes place when the skin comes into contact with a heat source. Burns can occur from many different sources. The most common sources that cause Burns are fire/flame, scalds, hot objects, electrical, and chemical agents, respectively. Burns is a common injury seen in emergency departments around the world. Even as emergency management improves, Burns continues to have significant morbidity and mortality.

Request for a Webex demo of the report @ https://www.delveinsight.com/report-store/burns-market

Burns Epidemiology Segmentation

DelveInsight's analysis indicates that the majority of Burns injury cases taking treatment are males due to most Burn cases occurring at the workplace making males more vulnerable to Burns. There were 411,066 male and 251,944 female cases of treated burn injuries in 2020 in the United States.

In the same year, the Burns severity-specific estimated cases were observed to be 144,536, 387,198, 19,890, and 111,386 for first-degree, second-degree, third-degree, and unspecified, respectively in the United States.

The Burns Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Incident Cases of Burns Patient Requiring Treatment 
• Gender-specific Incident Cases of Treated Burn Injuries
• Etiology-specific Incident Cases of Treated Burn Injuries
• Severity-specific Incident Cases of Treated Burn Injuries
• Incident Cases of Hospitalized Burns Patients

Know how Burns Epidemiological Trends are going to look like in 2030 for the 7 MM by downloading @ https://www.delveinsight.com/report-store/burns-market

Burns Market

In the current market scenario, the standard treatment for Burns involves medications, wound dressings, therapy, and surgery. The Burns treatment goal is to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The Burns treatment depends on the severity of the burn. Currently, some major pharmaceutical companies like Kerecis, Polynovo, Mallinckrodt, are marketing Burns treatment therapies like Kerecis Omega3, NovoSorb BMT, and Stratagraft.

Despite the widespread availability of safe and effective Burns medications and surgery options, pharmaceuticals like Cutiss AG, Skingenix, and many more are developing novel Burns treatment therapies. One major breakthrough therapeutic product DenovoSkin is being developed by CUTISS AG which is bio-engineered with a thick, double layer, robust structure. DenovoSkin is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medical Product (ATMP). DenovoSkin has successfully completed Phase I. Another therapeutic product is MW-III, by Skingenix, which is a topical product being evaluated for second-degree burns in adult patients. 

To know about more pipeline therapies under different development phases visit @ https://www.delveinsight.com/report-store/burns-market